IN2014DN05772A - - Google Patents

Info

Publication number
IN2014DN05772A
IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
Authority
IN
India
Prior art keywords
galectin
medicament
novel compounds
compounds
ligandsin
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of IN2014DN05772A publication Critical patent/IN2014DN05772A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN5772DEN2014 2012-01-25 2013-01-24 IN2014DN05772A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (de) 2012-01-25 2012-01-25 Neuartige Galectin-Hemmer aus Galactosiden
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
IN2014DN05772A true IN2014DN05772A (de) 2015-04-10

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5772DEN2014 IN2014DN05772A (de) 2012-01-25 2013-01-24

Country Status (8)

Country Link
US (1) US9353141B2 (de)
EP (2) EP2620443A1 (de)
JP (1) JP6158840B2 (de)
CN (1) CN104066743B (de)
CA (1) CA2854986C (de)
ES (1) ES2559857T3 (de)
IN (1) IN2014DN05772A (de)
WO (1) WO2013110704A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE390140T1 (de) 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2014100703A2 (en) 2012-12-20 2014-06-26 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US10253059B2 (en) * 2014-07-09 2019-04-09 Galecto Biotech Ab Hybrid galactoside inhibitor of galectins
CN113621005A (zh) * 2015-01-30 2021-11-09 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EP3423461A4 (de) * 2016-03-04 2020-03-25 Galectin Sciences, LLC Selenogalactosidverbindungen zur vorbeugung und behandlung von erkrankungen im zusammenhang mit galectin und verwendung davon
US10889610B2 (en) * 2016-07-12 2021-01-12 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
WO2018011093A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
BR112019023722A2 (pt) 2017-05-12 2020-05-26 Galectin Sciences, Llc Compostos para a prevenção e tratamento de doenças e o uso dos mesmos
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
CA3102155A1 (en) * 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
AU2019416330A1 (en) 2018-12-27 2021-07-01 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
CA2724064C (en) 2008-05-16 2016-05-17 Forskarpatent I Syd Ab Synthesis of galactoside inhibitors
CN102439021B (zh) 2009-04-28 2015-09-02 格莱克特生物技术公司 半乳凝素的新型半乳糖苷抑制剂
CA2884802A1 (en) 2012-10-31 2014-05-08 Galecto Biotech Ab Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Also Published As

Publication number Publication date
EP2807176B1 (de) 2015-12-30
CA2854986A1 (en) 2013-08-01
JP2015504909A (ja) 2015-02-16
CA2854986C (en) 2019-09-17
US20140336146A1 (en) 2014-11-13
CN104066743B (zh) 2016-04-06
EP2807176A1 (de) 2014-12-03
WO2013110704A1 (en) 2013-08-01
CN104066743A (zh) 2014-09-24
ES2559857T3 (es) 2016-02-16
EP2620443A1 (de) 2013-07-31
JP6158840B2 (ja) 2017-07-05
US9353141B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
IN2014DN05772A (de)
AU2012214029A8 (en) Rorgammat inhibitors
MD20140002A2 (ro) Indazoli
MY160241A (en) 5-alkynyl-pyrimidines
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
PH12016500225A1 (en) Novel quinoline-substituted compound
NZ705135A (en) Heteroaryl compounds and methods of use thereof
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
IN2014MN02459A (de)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
IN2015DN01151A (de)
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX340577B (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
MX2014002988A (es) Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno.
MX349548B (es) Compuestos de tienopirimidina.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.